drugset / Trial / NCT00790335

Summary

The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.

Timeline

Start
2009-11
Primary completion
2017-01
Completion
2017-01

Outcome

Missed primary endpoint

registry analysis (superiority test); A-Intervention vs B-Control; p = 0.56; Risk Ratio (RR) 0.96 (95% CI 0.82 to 1.11); Cochran-Mantel-Haenszel NCT00790335 ↗

paper syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ratio, 0.96; 95% confidence interval [CI], 0.82 to 1.11; P=0.56). PMID 29211671 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.01 mg/kg Other
Subject Alteplase Protein / enzyme biologic 1 mg Other
Subject Alteplase Protein / enzyme biologic 25 mg Other
Subject Alteplase Protein / enzyme biologic 35 mg Other